Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Avalo Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Avalo Therapeutics, Inc.’s stock price such as:

• Avalo Therapeutics, Inc.’s current stock price and volume
• Why Avalo Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for AVTX from analysts
• AVTX’s stock price momentum as measured by its relative strength

About Avalo Therapeutics, Inc. (AVTX)

Before we jump into Avalo Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Want to learn more about Avalo Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Avalo Therapeutics, Inc..

Avalo Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Avalo Therapeutics, Inc.’s stock price was $18.250.

Avalo Therapeutics, Inc. is down 5.88% from its previous closing price of $19.390.

During the last market session, Avalo Therapeutics, Inc.’s stock traded between $18.240 and $19.730. Currently, there are approximately 20.11 million shares outstanding for Avalo Therapeutics, Inc..

Avalo Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Avalo Therapeutics, Inc. Stock Price History

Avalo Therapeutics, Inc.’s (AVTX) price is currently down 1.24% so far this month.

During the month of July, Avalo Therapeutics, Inc.’s stock price has reached a high of $20.650 and a low of $17.230.

Over the last year, Avalo Therapeutics, Inc. has hit prices as high as $24.270 and as low as $7.514. Year to date, Avalo Therapeutics, Inc.’s stock is up 0.5%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Avalo Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Avalo Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Avalo Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Avalo Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Avalo Therapeutics, Inc. (AVTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Avalo Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Avalo Therapeutics, Inc. has a weighted four-quarter relative price strength of 27.48%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how Avalo Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Avalo Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Avalo Therapeutics, Inc.’s stock price is $18.250, which is down 5.88% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Avalo Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.